Bruker announced the release of new Biopharma Compass 2.0 (BPC 2.0) software that automates biopharmaceutical characterization workflows for high resolution mass spectrometry. The BPC 2.0 solution is more comprehensive in scope, as it unifies data acquired from the two most relevant and perfectly complementary mass spectrometry methods for the characterization of biologics, MALDI-TOF/TOF and ESI-UHR-QTOF. BPC 2.0 offers a new 3D feature finder, supports 21CFR Part 11 compliance, full integration of UV and MS data and easy-to-use wizards allow defining methods from acquisition to report generation required by the biopharmaceutical industry. Biopharma Compass 2.0 unifies the data acquisition, data analysis and result reporting of the most often used biopharma workflows including, Intact mass analysis of large proteins, antibodies or antibody fragments to screen for and identify sequence, errors or post-translational modifications (PTM) quickly. Coupled with Bruker's SNAP-II algorithm for monoisotopic mass determination (up to the heavy chain), this workflow delivers PTM profiles quickly and with minimal experimental alteration, Top-down and middle-down screening of large proteins with both ESI-UHR-QTOF and MALDI-TOF/TOF for sequence confirmation, and to find protein N- or C-terminal odifications, Peptide screening with routine PTM and artifact quantification with dynamic range, fully integrating LC-UV and MS, MS/MS data in predefined report formats.